文献速递造血干细胞移植与细胞治疗

贝鲁舒地尔治疗闭塞性细支气管炎综合征的临床反应:两项前瞻性试验的联合分析

Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.
PubMed 文献 · Blood Adv · 2022-01-01

该联合分析纳入两项贝鲁舒地尔前瞻性临床试验中59例闭塞性细支气管炎综合征患者,评估肺特异性缓解情况。结果显示最佳总缓解率为32%,且缓解率与基线NIH肺评分呈负相关(评分1为50%,评分2为17%,评分3为0%,P=0.006)。

要点

  • 贝鲁舒地尔治疗BOS的肺特异性最佳总缓解率为32%(部分缓解17%,完全缓解15%)。
  • 基线NIH肺评分1、2、3的缓解率分别为50%、17%、0%(P=0.006)。
  • 肺功能评估与患者症状评分间未发现显著相关性。

核心结论

  • 贝鲁舒地尔治疗与BOS患者的肺特异性临床缓解相关,且缓解更常见于疾病较轻者。
  • BOS患者的治疗缓解评估优化仍是一大挑战。

研究设计与样本

  • 联合分析两项贝鲁舒地尔前瞻性临床试验,共纳入59例闭塞性细支气管炎综合征患者。
  • 入组时预测FEV1百分比≤79%,且研究者归因于cGVHD的肺部病变。

主要发现

  • 根据NIH缓解标准,肺部cGVHD最佳总缓解率为32%(部分缓解17%,完全缓解15%)。
  • 基线NIH肺评分1的缓解率为50%,评分2为17%,评分3为0%(P=0.006)。
  • 多变量分析中,男性、较低基线NIH肺评分及入组前对上一线cGVHD治疗部分缓解与更高的肺特异性缓解率相关。
  • 肺功能评估与患者症状指标(NIH肺部症状评分或Lee症状量表肺部评分)之间未发现显著相关性。

局限性

  • BOS患者的治疗缓解评估优化仍是一大挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) of the lung, or bronchiolitis obliterans syndrome (BOS), is a high-risk disease manifestation associated with poor outcomes. Currently available treatments have demonstrated limited clinical efficacy in this setting. Belumosudil is a novel oral selective rho-associated coiled-coil-containing protein kinase-2 inhibitor that was recently approved by the US Food and Drug Administration in the treatment of cGVHD. We identified 59 subjects with BOS who were enrolled and treated in 2 prospective clinical trials of belumosudil. Patients with BOS had a percentage predicted forced expiratory volume in 1 second (FEV1) of ≤79% at enrollment and clinician attribution of lung disease owing to cGVHD. The National Institutes of Health (NIH) cGVHD lung scores at enrollment were 1 (n = 30, 59%), 2 (n = 23, 39%), or 3 (n = 6, 10%). According to NIH response criteria, the best overall response rate (ORR) for lung cGVHD was 32% (partial response: 17%; complete response: 15%). Response rates were inversely proportional to baseline NIH GVHD lung score at enrollment (lung score 1: ORR 50%; lung score 2: ORR 17%, lung score 3: ORR 0%) (P = .006). In multivariable analysis, male sex, lower baseline NIH cGVHD lung score, and partial response to previous line of cGVHD therapy before enrollment were associated with higher rates of lung-specific response. No significant correlation was identified between pulmonary function evaluations and measures of patient symptoms (NIH lung symptom score or Lee Symptom Scale score for lung). In conclusion, belumosudil treatment was associated with lung-specific clinical responses for subjects with BOS, which were more commonly observed in less advanced disease. Optimization of treatment response evaluations remains a challenge in patients with BOS.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. DeFilipp Z, Kim HT, Yang Z, et al. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials. Blood Adv. 2022. PMID: 36083121. doi:10.1182/bloodadvances.2022008095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。